Marshall Wace, LLP Clearside Biomedical, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.08 - $1.58 $6,853 - $10,026	-6,346 Reduced 9.27%	62,117 $80,000
Q1 2024 May 15, 2024	BUY	$1.2 - $2.02 $82,155 - $138,295	68,463 New	68,463 $104,000
Q3 2022 Nov 14, 2022	SELL	$1.08 - $1.83 $70,355 - $119,213	-65,144 Reduced 29.91%	152,671 $173,000
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.49 $252,480 - $483,597	-194,216 Reduced 47.14%	217,815 $321,000
Q1 2022 May 16, 2022	BUY	$1.35 - $2.88 $556,241 - $1.19 Million	412,031 New	412,031 $943,000
Q4 2021 Feb 14, 2022	SELL	$2.72 - $5.72 $145,449 - $305,871	-53,474 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.83 - $7.2 $854,750 - $1.27 Million	-176,967 Reduced 76.79%	53,474 $321,000
Q2 2021 Aug 13, 2021	SELL	$2.32 - $5.38 $240,507 - $557,728	-103,667 Reduced 31.03%	230,441 $1.12 Million
Q1 2021 May 17, 2021	BUY	$2.24 - $4.25 $748,401 - $1.42 Million	334,108 New	334,108 $825,000

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $52.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.